Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation. PGF2α has been shown to stimulate the growth of melanocyte dendrites, increasing dendricity even at low doses, as well as enhancing tyrosinase activity and quantity, thereby promoting repigmentation. Studies on the use of 0.005% latanoprost gel in both children and adults with vitiligo have demonstrated effective repigmentation without reported side effects.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Area of repigmentation
Timeframe: From enrollment to the end of treatment at 12 weeks
Pattern of repigmentation
Timeframe: From enrollment to the end of treatment at 12 weeks
Number of lesions with repigmentation
Timeframe: From enrollment to the end of treatment at 12 weeks